Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Cenexi reports an EBITDA breakeven for the quarter
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Athena is also exploring the use of this technology for expanded carrier screening
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
The submission is supported by results from the Phase 3b APEX study
Subscribe To Our Newsletter & Stay Updated